Adjuvant activity of chicken interleukin-12 co-administered with infectious bursal disease virus recombinant VP2 antigen in chickens

Su, Bor Sheu; Chiu, Hua Hsien; Lin, Chen‐Ju; Shien, Jui Hung; Yin, Hao; Lee, Long Huw

doi:10.1016/j.vetimm.2010.10.001

Cited by 15 publications

(15 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the other hands, our previous results demonstrated that rchIL-12, not in a fusion protein, was produced in rFPV-infected DF1 cells, but it was not secreted into the medium. 10,11 Thus, these results and the present study on the rchIL-12/eGFP protein suggests that specific gene expression patterns after transfection may depend on the host cell targets. In a study on the effect of DMSO on transcription level of HBsAg gene expression, Wang et al (2006) 19 indicated that some post-translation events, such as the saturation of the secretion pathway, the inhibition of DMSO on HBsAg secretion pathway, and the limitation of post-translation modification of protein, could involve in restriction on the HBsAg secretion.…”

Section: Purification and Bioactivity Assay Of The Fusion Proteinsupporting

confidence: 57%

See 1 more Smart Citation

Production and characterization of active recombinant interleukin‐12/eGFP fusion protein in stably‐transfected DF1 chicken cells

Chen

Shen

et al. 2015

Biotechnology Progress

Self Cite

View full text Add to dashboard Cite

The adjuvant activity of chicken interleukin-12 (chIL-12) protein has been described as similar to that of mammalian IL-12. Recombinant chIL-12 can be produced using several methods, but chIL-12 production in eukaryotic cells is lower than that in prokaryotic cells. Stimulating compounds, such as dimethyl sulfoxide (DMSO), can be added to animal cell cultures to overcome this drawback. In this study, we constructed a cell line, DF1/chIL-12 which stably expressed a fusion protein, chIL-12 and enhanced green fluorescent protein (eGFP) connected by a (G4 S)3 linker sequence. Fusion protein production was increased when cells were cultured in the presence of DMSO. When 1 × 10(6) DF1/chIL-12 cells were inoculated in a T-175 flask containing 30 mL of media, incubated for 15 h, and further cultivated in the presence of 4% DMSO for 48 h, the production of total fusion protein was mostly enhanced compared with the production of total fusion protein by using cell lysates induced with DMSO at other concentrations. The concentrations of the unpurified and purified total fusion proteins in cell lysates were 2,781 ± 2.72 ng mL(-1) and 2,207 ± 3.28 ng mL(-1) , respectively. The recovery rate was 79%. The fusion protein stimulated chicken splenocytes to produce IFN-γ, which was measured using an enzyme-linked immunosorbent assay, in the culture supernatant, indicating that treating DF1/chIL-12 cells with DMSO or producing chIL-12 in a fusion protein form does not have adverse effects on the bioactivity of chIL-12.

show abstract

Section: Purification and Bioactivity Assay Of The Fusion Proteinsupporting

confidence: 57%

“…Thus, recombinant chIL-12 (rchIL-12) appears to be a promising vaccine adjuvant. 11 However, the aforementioned expression systems have disadvantages. Recombinant proteins produced in bacteria are often expressed in inclusion bodies and do not undergo posttranslational modification.…”

Section: Introductionmentioning

confidence: 99%

Production and characterization of active recombinant interleukin‐12/eGFP fusion protein in stably‐transfected DF1 chicken cells

Chen

Shen

et al. 2015

Biotechnology Progress

Self Cite

View full text Add to dashboard Cite

show abstract

“…FPV is also easy to produce, and technologies for large-scale production are available. Some cytokines such as IL-1 (Park et al, 2006), IL-2 (Saade et al, 2008), IL-12 (Su et al, 2011), interferon-gamma (IFN-c) (Ma et al, 2008), and granulocyte-macrophage colony-stimulating factor (Tan et al, 2009), have been reported to be effective immunomodulators in animal models or clinical tests. Some cytokines such as IL-1 (Park et al, 2006), IL-2 (Saade et al, 2008), IL-12 (Su et al, 2011), interferon-gamma (IFN-c) (Ma et al, 2008), and granulocyte-macrophage colony-stimulating factor (Tan et al, 2009), have been reported to be effective immunomodulators in animal models or clinical tests.…”

mentioning

confidence: 99%

“…A recombinant fowlpox virus (rFPV) vaccine alone, however, is limited in that it often generates only weak immune responses, particularly the cellular response, in the absence of suitable adjuvants (Leong et al, 1994;Ma et al, 2008). Cytokine adjuvants have been widely used to promote the induction of immune responses and enhance the immunoprotective effects of rFPV vaccines (Noll & Autenrieth, 1996;Su et al, 2011). Cytokine adjuvants have been widely used to promote the induction of immune responses and enhance the immunoprotective effects of rFPV vaccines (Noll & Autenrieth, 1996;Su et al, 2011).…”

mentioning

confidence: 99%

“…A recombinant fowlpox virus (rFPV) vaccine alone, however, is limited in that it often generates only weak immune responses, particularly the cellular response, in the absence of suitable adjuvants (Leong et al, 1994;Ma et al, 2008). Some cytokines such as IL-1 (Park et al, 2006), IL-2 (Saade et al, 2008), IL-12 (Su et al, 2011), interferon-gamma (IFN-c) (Ma et al, 2008), and granulocyte-macrophage colony-stimulating factor (Tan et al, 2009), have been reported to be effective immunomodulators in animal models or clinical tests. Cytokine adjuvants have been widely used to promote the induction of immune responses and enhance the immunoprotective effects of rFPV vaccines (Noll & Autenrieth, 1996;Su et al, 2011).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Immune responses of chickens inoculated with a recombinant fowlpox vaccine coexpressing glycoprotein B of infectious laryngotracheitis virus and chicken IL-18

Chen

Cui

Bao-an

et al. 2011

FEMS Immunol Med Microbiol

View full text Add to dashboard Cite

Infectious laryngotracheitis virus (ILTV) is an alphaherpesvirus that causes severe and economically significant respiratory disease in poultry worldwide. Herein, the immunogenicity of two recombinant fowlpox viruses (rFPV-gB and rFPV-gB/IL18) containing ILTV glycoprotein B (gB) and chicken interleukin-18 (IL-18) were investigated in a challenge model. One-day-old specific-pathogen-free chickens were vaccinated by wing-web puncture with the two rFPVs and challenged with the virulent ILTV CG strain. There were differences in antibody levels elicited by either rFPV-gB/IL18 or rFPV-gB as determined using ELISA. The ratios of CD4(+) to CD8(+) in chickens immunized with rFPV-gB/IL18 were higher (P < 0.05) than in those immunized with rFPV-gB, and the level of proliferative response of the T cells in the rFPV-gB/IL18-vaccinated group was higher (P < 0.05) than that in the rFPV-gB group. All chickens immunized with rFPV-gB/IL18 were protected (10/10), whereas only eight of 10 of the chickens immunized with the rFPV-gB were protected. The results showed that the protective efficacy of the rFPV-gB vaccine could be enhanced by simultaneous expression of chicken IL-18.

show abstract

Evolution of developmental and comparative immunology in poultry: The regulators and the regulated

Lee

Lillehoj

2023

Developmental & Comparative Immunology

View full text Add to dashboard Cite

Adjuvant activity of chicken interleukin-12 co-administered with infectious bursal disease virus recombinant VP2 antigen in chickens

Cited by 15 publications

References 22 publications

Production and characterization of active recombinant interleukin‐12/eGFP fusion protein in stably‐transfected DF1 chicken cells

Production and characterization of active recombinant interleukin‐12/eGFP fusion protein in stably‐transfected DF1 chicken cells

Immune responses of chickens inoculated with a recombinant fowlpox vaccine coexpressing glycoprotein B of infectious laryngotracheitis virus and chicken IL-18

Evolution of developmental and comparative immunology in poultry: The regulators and the regulated

Contact Info

Product

Resources

About